Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer

Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Aung Naing(The University of Texas MD Anderson Cancer Center), Robert L. Coleman(Texas Oncology), David M. Gershenson(The University of Texas MD Anderson Cancer Center), David S. Hong(The University of Texas MD Anderson Cancer Center), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Amanda L. Brink(The University of Texas MD Anderson Cancer Center), Bülent Yılmaz(The University of Texas MD Anderson Cancer Center), Apostolia M. Tsimberidou(The University of Texas MD Anderson Cancer Center), Siqing Fu(The University of Texas MD Anderson Cancer Center), Fechukwu Akhmedzhanov(The University of Texas MD Anderson Cancer Center), Brett Carter(RMIT University), Heather Lin(The University of Texas MD Anderson Cancer Center), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Shubham Pant(The University of Texas MD Anderson Cancer Center), Anil K. Sood(The University of Texas MD Anderson Cancer Center), Jing Gong(174th hospital of the People's Liberation Army), Jatin J. Shah(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Lacey McQuinn(The University of Texas MD Anderson Cancer Center), Cheuk Hong Leung(The University of Texas MD Anderson Cancer Center)
Gynecologic Oncology
November 21, 2022
Cited by 8


Related Papers